drugset / Trial / NCT00140647

The Study of Atherosclerosis With Ramipril and Rosiglitazone

NCT00140647

RandomizedFactorialDouble-blindPrevention

Summary

The purpose of this study is to determine if ramipril and/or rosiglitazone retard the progression of atherosclerosis as evaluated by serial carotid intermedial thickness measurements.

Timeline

Start
2001-07
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 15 mg
Subject Rosiglitazone Small molecule 8 mg